Mabcure Stock Performance
| MBCI Stock | USD 0.0001 0.00 0.00% |
MabCure holds a performance score of 6 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -1.9, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning MabCure are expected to decrease by larger amounts. On the other hand, during market turmoil, MabCure is expected to outperform it. Use MabCure standard deviation and the relationship between the jensen alpha and day typical price , to analyze future returns on MabCure.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in MabCure are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak fundamental indicators, MabCure demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 3415.00 | |
| Total Cashflows From Investing Activities | 53.2 K |
MabCure |
MabCure Relative Risk vs. Return Landscape
If you would invest 0.01 in MabCure on October 28, 2025 and sell it today you would earn a total of 0.00 from holding MabCure or generate 0.0% return on investment over 90 days. MabCure is currently generating 2.1164% in daily expected returns and assumes 26.6888% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than MabCure, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
MabCure Target Price Odds to finish over Current Price
The tendency of MabCure Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.0001 | 90 days | 0.0001 | about 69.57 |
Based on a normal probability distribution, the odds of MabCure to move above the current price in 90 days from now is about 69.57 (This MabCure probability density function shows the probability of MabCure Pink Sheet to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days MabCure has a beta of -1.9. This indicates as returns on its benchmark rise, returns on holding MabCure are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, MabCure is expected to outperform its benchmark. In addition to that MabCure has an alpha of 2.1403, implying that it can generate a 2.14 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). MabCure Price Density |
| Price |
Predictive Modules for MabCure
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as MabCure. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of MabCure's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
MabCure Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. MabCure is not an exception. The market had few large corrections towards the MabCure's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold MabCure, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of MabCure within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 2.14 | |
β | Beta against Dow Jones | -1.9 | |
σ | Overall volatility | 0.000082 | |
Ir | Information ratio | 0.07 |
MabCure Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of MabCure for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for MabCure can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| MabCure is way too risky over 90 days horizon | |
| MabCure has some characteristics of a very speculative penny stock | |
| MabCure appears to be risky and price may revert if volatility continues | |
| MabCure has high likelihood to experience some financial distress in the next 2 years | |
| MabCure currently holds 304.98 K in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. MabCure has a current ratio of 0.17, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist MabCure until it has trouble settling it off, either with new capital or with free cash flow. So, MabCure's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like MabCure sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for MabCure to invest in growth at high rates of return. When we think about MabCure's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 500 K. Net Loss for the year was (12.26 M) with profit before overhead, payroll, taxes, and interest of 500 K. | |
| MabCure currently holds about 146.44 K in cash with (61.39 K) of positive cash flow from operations. |
MabCure Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of MabCure Pink Sheet often depends not only on the future outlook of the current and potential MabCure's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. MabCure's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 62.1 M | |
| Cash And Short Term Investments | 146.4 K |
MabCure Fundamentals Growth
MabCure Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of MabCure, and MabCure fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MabCure Pink Sheet performance.
| Return On Equity | -1.25 | |||
| Return On Asset | -0.0422 | |||
| Operating Margin | (1.42) % | |||
| Current Valuation | 643.64 K | |||
| Shares Outstanding | 64.36 M | |||
| Price To Earning | (0.02) X | |||
| Price To Book | 0.06 X | |||
| Price To Sales | 1.29 X | |||
| Revenue | 500 K | |||
| EBITDA | (12.05 M) | |||
| Cash And Equivalents | 146.44 K | |||
| Total Debt | 304.98 K | |||
| Debt To Equity | 0.08 % | |||
| Book Value Per Share | 0.06 X | |||
| Cash Flow From Operations | (61.39 K) | |||
| Earnings Per Share | (0.19) X | |||
| Total Asset | 4.81 M | |||
About MabCure Performance
By evaluating MabCure's fundamental ratios, stakeholders can gain valuable insights into MabCure's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if MabCure has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if MabCure has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
MabCure Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. MabCure Inc. was founded in 2006 and is based in White Plains, New York. Mabcure is traded on OTC Exchange in the United States.Things to note about MabCure performance evaluation
Checking the ongoing alerts about MabCure for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for MabCure help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MabCure is way too risky over 90 days horizon | |
| MabCure has some characteristics of a very speculative penny stock | |
| MabCure appears to be risky and price may revert if volatility continues | |
| MabCure has high likelihood to experience some financial distress in the next 2 years | |
| MabCure currently holds 304.98 K in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. MabCure has a current ratio of 0.17, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist MabCure until it has trouble settling it off, either with new capital or with free cash flow. So, MabCure's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like MabCure sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for MabCure to invest in growth at high rates of return. When we think about MabCure's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 500 K. Net Loss for the year was (12.26 M) with profit before overhead, payroll, taxes, and interest of 500 K. | |
| MabCure currently holds about 146.44 K in cash with (61.39 K) of positive cash flow from operations. |
- Analyzing MabCure's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MabCure's stock is overvalued or undervalued compared to its peers.
- Examining MabCure's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MabCure's management team can have a significant impact on its success or failure. Reviewing the track record and experience of MabCure's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MabCure's pink sheet. These opinions can provide insight into MabCure's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for MabCure Pink Sheet analysis
When running MabCure's price analysis, check to measure MabCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MabCure is operating at the current time. Most of MabCure's value examination focuses on studying past and present price action to predict the probability of MabCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MabCure's price. Additionally, you may evaluate how the addition of MabCure to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |